Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Harish Murthy

Pulmonary Disease San Jose, CA Medical Doctor

NPI 1922074061 CMS profile 223620

2520 Samaritan Dr, Ste 104B, San Jose, CA 95124

Open in the dashboard

General payments

$991

12 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Harish Murthy of San Jose, CA is reported in the CMS Open Payments database as having received $991 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $146 2
2023 General $327 3
2021 General $177 3
2019 General $342 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harish Murthy
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Harish Murthy were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Harish Murthy Pulmonary Disease median Middle half National median
2019 $342 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $177 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $327 $419 $114–$1,659 $160
2024 $146 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $269 3 payments
  2. La Jolla Pharmaceutical Company $187 1 payment
  3. Portola Pharmaceuticals, Inc. $181 2 payments
  4. NuVasive, Inc. $150 1 payment
  5. Stryker Corporation $140 1 payment
  6. Electromed, Inc. $27 2 payments
  7. GlaxoSmithKline, LLC. $21 1 payment
  8. Inspire Medical Systems, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $991 12 payments
Products named General payments · program years 2019–2024
  1. GIAPREZA $187 1 payment
  2. ANDEXXA Hematology/Neurology $181 2 payments
  3. ALIF $150 1 payment
  4. ANDEXXA Rare Disease $146 2 payments
  5. TREVO $140 1 payment
  6. SAPHNELO $123 1 payment
  7. SMARTVEST $27 2 payments
  8. TRELEGY ELLIPTA $21 1 payment
  9. INSPIRE $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,564

Median for Pulmonary Disease: 936

Drug cost

$710,924

Median for Pulmonary Disease: $487,987

Branded share of claims

55.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 295 $307,965
Ofev Nintedanib Esylate Brand 12 $174,146
Breo Ellipta Fluticasone/Vilanterol Brand 164 $106,425
Spiriva Handihaler Tiotropium Bromide Brand 18 $25,759
Spiriva Respimat Tiotropium Bromide Brand 21 $21,602
Incruse Ellipta Umeclidinium Bromide Brand 28 $17,394
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 26 $13,236
Symbicort Budesonide/Formoterol Fumarate Brand 24 $13,216
Wixela Inhub Fluticasone Propion/Salmeterol Brand 50 $7,229
Montelukast Sodium Generic 385 $6,138

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$474,151

Medicare's payments for the services billed

Medicare patients

1,249

Average age 76

Services billed

3,141

604 women, 645 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 48%
Arthritis 47%
Diabetes 41%
Atrial fibrillation 32%
Heart failure 29%
Chronic kidney disease 28%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record